Literature DB >> 12781336

Human MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activities.

Naomi Morita1, Toshio Yasumori, Kazuo Nakayama.   

Abstract

The two most frequently observed single nucleotide polymorphisms (SNPs) of the human multidrug resistance 1 (MDR1) gene are 2677G/T/A (893Ala/Ser/Thr) and 3435C/T (no amino acid substitution). In this study, six forms of MDR1 cDNAs with the SNPs were expressed in LLC-PK1 cells and their transport activities were determined. Nearly identical amounts of the recombinant MDR1 proteins were expressed in the established cell lines using the Flp recombinase, which integrates a gene of interest at a specific genomic location. Four structurally diverse compounds: verapamil, digoxin, vinblastine and cyclosporin A, were examined for transcellular transport activities and intracellular accumulation. No significant differences were observed between cells expressing five polymorphic types of the MDR1 cDNAs (2677G/3435T, 2677A/3435C, 2677A/3435T, 2677T/3435C, 2677T/3435T) and cells expressing the wild-type (2677G/3435C). These results suggested that the two frequently observed MDR1 SNPs had no effect on the transport activities of MDR1 proteins expressed in LLC-PK1 cells in vitro, and other genetic or environmental factors might control the expression of MDR1 and the in vivo activity of MDR1.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781336     DOI: 10.1016/s0006-2952(03)00178-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  24 in total

1.  Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.

Authors:  Nicole Soranzo; Gianpiero L Cavalleri; Michael E Weale; Nicholas W Wood; Chantal Depondt; Richard Marguerie; Sanjay M Sisodiya; David B Goldstein
Journal:  Genome Res       Date:  2004-06-14       Impact factor: 9.043

2.  MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children.

Authors:  Anna Wasilewska; Grzegorz Zalewski; Lech Chyczewski; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2006-10-17       Impact factor: 3.714

3.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 4.  Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis.

Authors:  V Annese; M-R Valvano; O Palmieri; A Latiano; F Bossa; A Andriulli
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

5.  Relationship between loperamide-induced sedative effect and digoxin pharmacokinetics in healthy Japanese subjects.

Authors:  Michiya Kobayashi; Hiroshi Saitoh; Michiko Yamaguchi; Takeshi Saito; Hiroyoshi Fujita; Manabu Suno; Kazuo Matsubara; Bruce J Aungst
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

6.  Substrate-dependent effects of human ABCB1 coding polymorphisms.

Authors:  Jason M Gow; Laura M Hodges; Leslie W Chinn; Deanna L Kroetz
Journal:  J Pharmacol Exp Ther       Date:  2008-02-20       Impact factor: 4.030

Review 7.  A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function.

Authors:  King Leung Fung; Michael M Gottesman
Journal:  Biochim Biophys Acta       Date:  2009-03-11

8.  Maternal medication use, fetal 3435 C>T polymorphism of the ABCB1 gene, and risk of isolated septal defects in a Han Chinese population.

Authors:  Chuan Wang; Kaiyu Zhou; Liang Xie; Yifei Li; Yalan Zhan; Lina Qiao; Chaoyi Qin; Ruiqi Liu; Yimin Hua
Journal:  Pediatr Cardiol       Date:  2014-04-17       Impact factor: 1.655

9.  Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.

Authors:  Rebekah L Benish; Benigno Rodriguez; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Infect Genet Evol       Date:  2009-10-09       Impact factor: 3.342

10.  Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.

Authors:  Caroline Solas; Nicolas Simon; Marie-Pierre Drogoul; Sylvie Quaranta; Véronique Frixon-Marin; Véronique Bourgarel-Rey; Corinne Brunet; Jean-Albert Gastaut; Alain Durand; Bruno Lacarelle; Isabelle Poizot-Martin
Journal:  Br J Clin Pharmacol       Date:  2007-05-22       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.